Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARAMBA
2025-521530-28-00Phase 2Authorised
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Nov 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idecabtagene vicleucel in systemic lupus erythematosus (SLE), Autoimmune Myopathies, dermatomyositis (DM) and 4 more, sponsored by Universitätsklinikum Erlangen. Primary endpoint: Incidence of serious CAR-T related toxicities. Planned start Nov 2025; status: authorised.
02
Drugs
idecabtagene vicleucel
03
Conditions
systemic lupus erythematosus (SLE)Autoimmune Myopathiesdermatomyositis (DM)polymyositis (PM)systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2025-521530-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521530-28-00.